₹14959.9 -89.8 -0.6%
Last Trade - 13/04/21
| Market Cap | £3.09bn |
| Enterprise Value | £2.91bn |
| Revenue | £405.3m |
| Position in Universe | 124th / 3106 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Mar | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 22,886 | 26,456 | 29,387 | 33,071 | 36,786 | 40,931 | 43,418 | 48,750 | +12.3% | ||
| +19.6 | +12.1 | +8.4 | +34.5 | +19.3 | +33.6 | +17.7 | +13.3 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Abbott India Limited is a healthcare company engaged in pharmaceuticals business. The Company has a portfolio of science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. Its business operations are divided into four business divisions: Women's Health & Gastrointestine, Gastroenterology and Hepatic Care; Specialty Care; GenNext & Vaccines, and Consumer Care. Women's Health & Gastrointestine, Gastroenterology and Hepatic Care division has a mix of global and local brands present in the pregnancy, constipation and liver diseases segments. The Specialty Care division consists of a range of products in the treatment of central nervous system and metabolic disorders. The GenNext division focuses on several therapy areas, including pain management, vitamins and pregnancy. Its vaccines include Enteroshield (typhoid vaccine) and Rotasure (rotavirus diarrhea vaccine). The Consumer Care division is present in the over the counter antacid segment.
| Last Annual | March 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | August 22, 1944 |
| Public Since | November 3, 1994 |
| No. of Shareholders: | 51,442 |
| No. of Employees: | 3,551 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | National Stock Exchange of India |
| Shares in Issue | 21,250,000 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 3-4 Corporate Park,Sion-Trombay Road Chembur, MUMBAI, 400051, India |
| Web | http://www.abbott.co.in/ |
| Phone | +91 22 38162000 |
| Contact | Krupa Anandpara (Compliance Officer, Company Secretary) |
| Auditors | S R B C & CO LLP |
As of 13/04/21, shares in Abbott India are trading at ₹14959.9, giving the company a market capitalisation of £3.09bn. This share price information is delayed by 15 minutes.
Shares in Abbott India are currently trading at ₹14959.9 and the price has moved by -12.45% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Abbott India price has moved by -44.94% over the past year.
Of the analysts with advisory recommendations for Abbott India, there are there are currently 5 "buy" , 1 "hold" and 2 "sell" recommendations. The overall consensus recommendation for Abbott India is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Abbott India is scheduled to issue upcoming financial results on the following dates:
The Abbott India dividend yield is 0.72% based on the trailing twelve month period.
Last year, Abbott India paid a total dividend of 0.107k, and it currently has a trailing dividend yield of 0.72%. Looking ahead, Abbott India has not announced an ex-dividend date yet.
Abbott India has yet to annouce their ex-dividend date. The historic dividend yield on Abbott India shares is currently 0.72%.
To buy shares in Abbott India you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Abbott India are currently trading at ₹14959.9, giving the company a market capitalisation of £3.09bn.
Here are the trading details for Abbott India:
Based on an overall assessment of its quality, value and momentum, Abbott India is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Abbott India are currently priced at ₹14959.9. At that level they are trading at 19.82% discount to the analyst consensus target price of 0.00.
Analysts covering Abbott India currently have a consensus Earnings Per Share (EPS) forecast of 328.637 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abbott India. Over the past six months, the relative strength of its shares against the market has been -24.11%. At the current price of ₹14959.9, shares in Abbott India are trading at -3.4% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Abbott India PE ratio based on its reported earnings over the past 12 months is 48.97. The shares are currently trading at ₹14959.9.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Abbott India's management team is headed by:
Here are the top five shareholders of Abbott India based on the size of their shareholding:
